Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Releases Earnings Results, Beats Expectations By $0.04 EPS

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) issued its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.04, Zacks reports. The company had revenue of $5.55 billion during the quarter, compared to analysts’ expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS stock traded up $0.04 during mid-day trading on Friday, reaching $22.11. 307,466 shares of the company’s stock traded hands, compared to its average volume of 683,644. The firm has a 50 day moving average price of $23.70 and a two-hundred day moving average price of $22.98. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 1.07. The firm has a market capitalization of $11.87 billion, a PE ratio of 11.45, a price-to-earnings-growth ratio of 4.26 and a beta of 0.76.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on FMS. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective on the stock. in a research report on Tuesday, July 28th. Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Sanford C. Bernstein raised their price target on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Finally, Truist Financial set a $25.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $23.57.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on kidney disease and dialysis services. The company provides hemodialysis and peritoneal dialysis treatments through a global network of outpatient dialysis clinics and supports patients with related care and medical services.

In addition to operating dialysis centers, Fresenius Medical Care develops and manufactures products used in renal care. Its portfolio includes dialysis machines, dialyzers, bloodlines, concentrates, solutions, pharmaceuticals and other disposable supplies.